Produktname:2,5,6-Trichloronicotinamide

IUPAC Name:2,5,6-trichloropyridine-3-carboxamide

CAS:142266-62-4
Molekulare Formel:C6H3Cl3N2O
Reinheit:95%+
Katalognummer:CM177898
Molekulargewicht:225.45

Packungseinheit Verfügbarer Vorrat Preis($) Menge
CM177898-100mg in stock ƓǤȎ
CM177898-250mg in stock ǤƓNJ
CM177898-1g in stock NJǵŢ
CM177898-5g 1-2 Weeks ƓůȎŢ
CM177898-25g 3-4 Weeks ǵưưư

Nur für den Einsatz in Forschung und Entwicklung..

Anfrage-Formular

   refresh    

Produkt-Details

CAS-Nr.:142266-62-4
Molekulare Formel:C6H3Cl3N2O
Schmelzpunkt:-
SMILES-Code:O=C(N)C1=C(Cl)N=C(Cl)C(Cl)=C1
Dichte:
Katalognummer:CM177898
Molekulargewicht:225.45
Siedepunkt:
Mdl-Nr.:
Lagerung:Store at 2-8°C.

Category Infos

Pyridines
Pyridine is a six-membered heterocyclic compound containing one nitrogen heteroatom. Pyridine and piperidine are the most frequently occurring heterocyclic building blocks in drug molecules. According to incomplete statistics, there are currently more than 180 drugs containing pyridine or piperidine structure that have been marketed, nearly 1/5 of the drugs approved for marketing in recent years contain these two structures.
Pyridine | C5H5N | Pyridine Supplier/Distributor/Manufacturer - Chemenu
Pyridine,Pyridine Wholesale,Pyridine for Sale,Pyridine Supplier,Pyridine Distributor,Pyridine Manufacturer
Pyridine is a basic heterocyclic organic compound with the chemical formula C5H5N. It is structurally related to benzene, with one methine group (=CH−) replaced by a nitrogen atom. It is a highly flammable, weakly alkaline, water-miscible liquid with a distinctive, unpleasant fish-like smell.

Column Infos

MK-1084
Merck initiates Phase 3 clinical trial of MK-1084, an investigational oral KRAS G12C inhibitor, in combination with KEYTRUDA® (pembrolizumab) for first-line treatment of certain patients with metastatic non-small cell lung cancer. KRAS mutations are one of the most frequently observed mutations in human cancers, making them a crucial target for precision oncology therapy.
MK-1084 is an investigational, oral covalent inhibitor of KRAS G12C, that is found in about 14% of people with non-small cell lung cancer. MK-1084 is currently under Phase 1 evaluation as monotherapy and as combined therapies in patients with KRAS G12C mutant advanced solid tumors.

Related Products